JV 1-36

Also Known As:

(PhAc-Tyr(1),Arg(2),Phe(4-Cl)(6),Arg(9),Abu(15),Nle(27),Arg(28),Har(29))hGH-RH(1-29)NH2; GHRH (1-29)-NH2, phenylacetyl-Tyr(1)-Arg(2)-Phe(4-Cl)(6)-Arg(9)-Abu(15)-Nle(27)-Arg(28)-Har(29)-; GHRH (1-29)-NH2, phenylacetyl-tyrosyl(1)-arginyl(2)-4-chlorophenylalanyl(6)-arginyl(9)-2-aminobutanoyl(15)-norleucyl(27)-arginyl(28)-homoarginyl(29)-; JV-1-36

Networked: 12 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Schally, A V: 7 articles (11/2001 - 03/2000)
2.	Varga, J L: 7 articles (11/2001 - 03/2000)
3.	Armatis, P: 5 articles (11/2001 - 03/2000)
4.	Groot, K: 4 articles (11/2001 - 05/2001)
5.	Halmos, G: 4 articles (10/2001 - 03/2000)
6.	Chatzistamou, I: 3 articles (11/2001 - 05/2001)
7.	Kovacs, Magdolna: 2 articles (01/2012 - 03/2006)
8.	Schally, Andrew V: 2 articles (01/2012 - 03/2006)
9.	Zarandi, Marta: 2 articles (01/2012 - 03/2006)
10.	Busto, R: 2 articles (10/2001 - 05/2001)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2022 - "Our study supports the anti-oxidative effects of JV-1-36 and contributes in our knowledge towards the in vitro effects of GHRHAnt in cancers." 12/01/2022 - "Herein, we investigate the effect of a commercially available GHRH antagonist, namely JV-1-36, in the redox status of the A549 human cancer cell line. " 12/20/2000 - "After 31 days of treatment with JV-1-36, tumor weight was inhibited by about 70% as compared with the controls. " 11/01/2001 - "All ten mice injected with cells treated with medium alone developed tumors within 23 days after cell inoculation, while only eight of ten and four of ten mice injected with cells exposed to JV-1-36 or JV-1-52, respectively, had tumors. " 11/01/2001 - "After 22 days of therapy with JV-1-36 or JV-1-52 at the dose of 20 microg/day, the final volume of UCI-107 tumors was significantly (P<0.05) decreased by 50.5% and 56%, respectively, compared to controls. "
2.	Breast Neoplasms (Breast Cancer) 10/01/2001 - "GHRH antagonists JV-1-36 and JV-1-38 inhibited growth of estrogen-independent MXT mouse mammary cancers in vivo, producing about 50% reduction in tumor volume (P < 0.05). " 10/01/2001 - "Antagonists of growth hormone-releasing hormone (GH-RH) inhibit the growth of various cancers by mechanism(s) that include the suppression of the insulin-like growth factors (IGF)-I and/or -II. In this study, nude mice bearing orthotopic implants of MDA-MB-435 human estrogen-independent breast carcinoma received 39 days of therapy with GH-RH antagonist JV-1-36 (20 microg/day). "
3.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/20/2000 - "In the present study we investigated various components of the IGF system in H-69 small cell lung carcinoma (SCLC) xenografted into nude mice and treated with GHRH antagonist JV-1-36. " 12/20/2000 - "Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma."
4.	Small Cell Carcinoma 09/08/2008 - "The aim of the study was to evaluate the influence of JV-1-36 (synthetic GH-RH antagonist) on proliferation and VEGF secretion by human neuroendocrine lung non-small cell carcinoma (NCI-H727) using cell culture model. "
5.	Carcinoma (Carcinomatosis) 11/01/2001 - "In the present study we investigated the effects of GH-RH antagonist JV-1-36 and VIP antagonist JV-1-52, on the growth and tumorigenicity of UCI-107 ovarian cell carcinoma xenografted into nude mice. "

Related Drugs and Biologics

1.	Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
2.	Estrogens (Estrogen)
3.	Insulin-Like Growth Factor I (IGF-1)
4.	MZ 5-156
5.	Somatostatin (Somatotropin Release-Inhibiting Factor)
6.	Insulin-Like Peptides
7.	vapreotide
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	JV 1-52
10.	MZ 4-71

Related Therapies and Procedures

1.	Therapeutics